Peptide Graded

Sermorelin

Does Sermorelin work?

Not properly: small studies and a 14-man report; the fat and muscle data come from a different drug.

CAnimal and cell studiesNot approvedas of 2026-10-27

For the use sermorelin is sold for today, raising growth hormone in healthy middle-aged adults to lose fat, build muscle and sleep better, there is no randomized trial of sermorelin. The controlled human data are physiology experiments in 7 to 13 people using GHRH, a retrospective series of 14 men on a combination regimen, and randomized trials of a different GHRH analog, tesamorelin, in HIV-associated belly fat (806 patients pooled) and in 60 obese adults. Class evidence from another drug in another population does not lift sermorelin itself above C. 1234567812

Sermorelin itself has almost no modern trial data. A 2017 retrospective chart review looked at men on testosterone therapy. They had been prescribed sermorelin together with GHRP-2 and GHRP-6. In the 14 men who met compliance criteria, IGF-1 rose from a mean of about 160 to about 240 ng/mL over roughly four months. There was no control group. The plan combined three drugs. No one measured body composition. 6

The body composition claims come from tesamorelin, a stabilized form of full-length GHRH. It was tested in people with HIV and belly fat linked to antiretroviral drugs. In a 412-patient randomized trial, tesamorelin cut visceral fat by 15 percent over 26 weeks. Placebo patients gained 5 percent. Triglycerides also improved. A pooled analysis of two phase 3 trials (806 patients) confirmed the visceral fat drop. It held at 52 weeks in those who stayed on the drug. Subcutaneous fat did not change. A secondary analysis found small gains in trunk muscle density and area. In 60 obese adults without HIV who had low growth hormone release, 12 months of tesamorelin reduced visceral fat and carotid artery wall thickness. It did not worsen glucose. A 2026 meta-analysis of five tesamorelin trials in HIV confirmed the effects on visceral fat, liver fat and lean mass. No one has tested whether compounded sermorelin at clinic doses does any of this. 2341112

Evidence checklist

  • Randomised controlled trial No sermorelin RCT for the sold use
  • Human study over 100 people Tesamorelin trial of 412; pooled 806 patients
  • More than one research group Tesamorelin and GHRH studies, several groups
  • Clinical outcomes, not surrogate markers Hormone levels; fat data from another drug
  • Human safety data beyond case reports Long-term adult use not studied

Read the full Sermorelin page

More on Sermorelin

Citations

  1. Front Endocrinol 2026: performance-enhancing peptides modulating the GH-IGF-1 axis, review pubmed.ncbi.nlm.nih.gov
  2. Falutz 2007, N Engl J Med: metabolic effects of tesamorelin in patients with HIV pubmed.ncbi.nlm.nih.gov
  3. Falutz 2010, J Clin Endocrinol Metab: pooled analysis of two phase 3 tesamorelin trials pubmed.ncbi.nlm.nih.gov
  4. Makimura 2012, J Clin Endocrinol Metab: tesamorelin in obese subjects with reduced GH secretion pubmed.ncbi.nlm.nih.gov
  5. Iovino 1989, J Clin Endocrinol Metab: repetitive GHRH restores the GH response in normal aging pubmed.ncbi.nlm.nih.gov
  6. Sigalos 2017, Am J Mens Health: GH secretagogue treatment raises IGF-1 in hypogonadal men pubmed.ncbi.nlm.nih.gov
  7. Steiger 1992, Neuroendocrinology: GHRH and somatostatin effects on sleep EEG and nocturnal hormones pubmed.ncbi.nlm.nih.gov
  8. Kerkhofs 1993, Am J Physiol: sleep-promoting effects of GHRH in normal men pubmed.ncbi.nlm.nih.gov
  9. Guldner 1997, Neurobiol Aging: reduced efficacy of GHRH on sleep in the elderly pubmed.ncbi.nlm.nih.gov
  10. Federal Register 2013: determination that Geref (sermorelin acetate) was not withdrawn for safety or effectiveness federalregister.gov
  11. Adrian 2019, J Frailty Aging: tesamorelin decreases muscle fat and increases muscle area in adults with HIV pubmed.ncbi.nlm.nih.gov
  12. Obes Res Clin Pract 2026: meta-analysis of tesamorelin RCTs in HIV-associated lipodystrophy pubmed.ncbi.nlm.nih.gov
  13. Clin Geriatr Med 1997: the somatopause, should GH deficiency in older people be treated pubmed.ncbi.nlm.nih.gov
  14. Russell-Aulet 1999, J Clin Endocrinol Metab: evidence for relative GHRH deficiency in aging pubmed.ncbi.nlm.nih.gov

Reference information only, not medical advice. Drawn from the Sermorelin article, fact-checked against the cited sources. No dosing anywhere on this site.